⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Melatonin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-05 — A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.: Preclinical study of MC1, a melatonin–catechol hybrid derivative, reports lifespan extension and improved muscle strength in model organisms via mitochondrial metabolic reprogramming and differential ROS regulation — a derivative rather than melatonin itself, and no human data. [animal-model] (novelty: 3)
- 2026-08-01 — The Mechanistic Study of Melatonin Regulation of p16Ink4a and Oct4 in Anti-Cellular Senescence.: Cell-based mechanistic study (MC3T3-E1 osteoblasts and BMSCs) reports melatonin downregulates p16Ink4a and upregulates OCT4 via VDR signaling, linking anti-senescence to stemness and osteogenic differentiation — no in vivo or human outcome data. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
28-sep-2026
novelty 2
per-area 2
strengthens
The Mechanistic Study of Melatonin Regulation of p16Ink4a and Oct4 in Anti-Cellular Senescence.
01-aug-2026
novelty 3
per-area 3
strengthens
Cadmium induces renal injury via a BMAL1-dependent inflammatory and senescence cascade: Attenuation by Lycium barbarum polysaccharide and melatonin.
25-jul-2026
novelty 2
per-area 2
strengthens
A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.
05-jul-2026
novelty 3
per-area 3
strengthens
Macrophage senescence and programmed cell death in atherosclerosis: Mechanisms, cross-talk, and emerging therapeutic strategies.
02-jul-2026
novelty 2
per-area 2
strengthens